Willing to Participate: What Gets in the Way
A Clinical Trials Awareness Month Report from Smart Patients
Clinical Trials Awareness Month is a chance to recognize the people who make medical progress possible: the principal investigators, study physicians, research nurses, coordinators, research pharmacists, and the patients who participate. Thank you.
This report is about a part of the recruitment process that usually goes unseen.
“I, too, have participated in two clinical trials. While I may not be the beneficiary, my prayer is that those who come after me will benefit. Thank you! All for the cure!”
Smart Patients often discuss their motivation to join clinical trials and share information about them with others. They recognize the benefits of accessing treatments being studied. They also run into practical barriers that are worth understanding.
When a patients is weighing whether to enroll in a clinical trial, the conversation that often decides the outcome is not with a coordinator or a study physician. It is with another patient. Someone who has already done the trial, or one like it. Someone who can describe what the visits actually involve, what the travel was like, what the bills looked like, what they wish they had known. In the Smart Patients community, those conversations happen constantly. Since the beginning of 2026 alone, our members have had over 100 of them.
Trial teams are not in these rooms. They cannot be. But the conversations are shaping who enrolls, who drops out, and who walks away before they ever fill out a screening form. That makes peer-to-peer dialogue a quiet but consequential layer of recruitment infrastructure, one that most sponsors do not see, measure, or support.
The members having these conversations are not casual participants. They read results from earlier-stage trials and compare designs across conditions. They share PubMed links and ClinicalTrials.gov entries. They prepare each other for enrollment conversations so they show up fluent in the specific trial, ready with the questions the write-up and consent form leave unanswered, and looking for the lived detail of what participation actually involves.
What follows is a look at what members are telling each other about clinical trials, organized around the barriers that come up most often. Each section ends with questions for the trial teams running the studies these patients want to join. The premise underneath all of it is the same: the patients you most want to reach are already talking to each other. What they say to each other depends on what they know. And what they know depends, in part, on you.
Gaps to Fill and Questions to Answer
Travel is a decision, not a given. More than one in four conversations in our community touched on the logistics of travel for trials. These decisions carry considerable emotional weight.
“I don’t travel since getting Sjögren’s but would fly anywhere to get real treatments.”
For many patients, a trial means traveling every four to six weeks, coordinating blood draws, tests and imaging, syncing care across institutions, and doing all of this while sick. The willingness is there. One member said: “I had a full-on panic attack about the idea of a trial today. It was easier to think about when it was in abstract terms. I also worry about how complicated travel is getting and how expensive it is. Will we be able to afford this for a couple of years?”
What moves patients from panic to participation is often not a consent form or a coordinator. It is another patient.
“The logistics can seem overwhelming. My first instinct was ‘I can’t do that...’ but it was another patient on the same trial that actually talked to me about her experience, how routine it had become, and how lots of patients do this.”
A patient who was about to walk away enrolled because another patient was able to make the abstract concrete. This is the peer infrastructure doing its work. That conversation was not arranged by the trial team. It happened because the online community exists. It helps members to say: "I sincerely believe one day my motivation will be high enough for me to take the travel on."
Questions: What would it look like for trial teams to make these conversations easier rather than incidental? Could prospective patients be connected with current participants earlier in the process? Could the lived logistics be made visible before the panic sets in?
Reading the consent form for what it doesn't say. Some members who travel for trials describe a gap between what the consent form covers and what they actually need to know before they can say yes.
“I also have found consents lacking in helping the out of towner really visualize the requirements for someone trying to travel. As long as you show up in the exam room, I don’t think the study team worries about what it took to get there or get home afterwards.”
As one member stated: "Not having clarity on reimbursements when you are 500 miles away? Crazy they would be recruiting when they don't have this nailed down." Members look to one another to fill these gaps when they can. But the information traveling between patients is only as good as what they have been told, and a patient who has not been told something accurate cannot pass on something accurate. "Study team nurses are generally a better resource. But I really had to push for specifics."
Questions: Can trial materials be more specific about what each visit requires? Can local labs be used for routine blood draws? Can the consent form or supplementary materials explain what happens if a flight is delayed, or provide an emergency contact for when logistics fall apart? Can reimbursement terms be presented with enough specificity that a patient 500 miles away can decide before enrolling?
Undisclosed costs and the uninsured patient. This was the largest concern discussed. Over half of trial-related conversations (53%) touched on cost and financial burden. For most patients, that means travel, accommodation, lost income, and time the trial does not cover. For uninsured patients, it can mean something more alarming.
One member, navigating a CAR-T trial as an uninsured self-pay participant, discovered after enrollment that a cancer center was attempting to retain costs she believed were covered by the trial sponsor.
“No fricking way, and the fight was on. I countered that every test and procedure done was included in the 40-page prospectus.”
She eventually recovered most of what was owed. But it took energy, time, and clarity about her rights to dispute the charges. That experience now lives in the community. The next uninsured member considering a similar trial has the benefit of her hard-earned knowledge. The trial sponsor does not know that knowledge exists, or what it is shaping.
Questions: How can the cost of trial participation be made transparent before enrollment? Can organizers present what participation will cost with and without insurance, so patients can decide with full information? What are the ethical and equity considerations when the burden of navigating undisclosed costs falls disproportionately on uninsured patients?
Who gets left out before they start. Eligibility came up in more than a third of conversations. Members spoke about the frustration of patients who want to participate, understand the trial, and manage the logistics, but are structurally excluded before they begin. Diagnosed, but with specific antibodies, can be excluded from autoimmune trials. Patients whose current treatment is working but who want options. Patients with overlapping conditions that trigger exclusion.
“I think the primary goal is to get them approved and then move from there. Which is understandable, but frustrating for those of us who have been continually neglected.”
Patients understand why criteria exist and the statistical requirements of trial design. They are not asking for scientific rigor to be compromised. They are asking for transparency about the reasoning, and a pathway forward.
Questions: When patients don't qualify, what is the next step? Can trial teams be explicit about why specific criteria exist, and what future trials might include patients previously excluded? Can patients who don't qualify hear directly from trial teams about what eligibility might look like in subsequent phases?
What This Suggests
There is a broad spectrum of willingness in this community, from patients building toward their first yes all the way up to people willing to relocate or even go to another country.
“While I would join in a heartbeat, some people are scared, it’s too difficult, can’t leave work, have a family to care for.”
What varies is access to the practical conditions that make participation possible. And much of what helps patients navigate those conditions does not come from a sponsor or a site. It comes from other patients. A community member who has flown in for a trial can describe what the day really involves. Someone who has fought a billing dispute can warn the next person what to watch for. Someone who didn't qualify can still pass along what they learned.
This is the part of recruitment that has been hiding in plain sight. The decisive conversation about a trial is often not the one in the exam room. It is the one happening among patients before they ever get there. Trial teams cannot run those conversations, but they can shape the information traveling through them. That changes what patient engagement should mean. It is not only about reaching patients with materials. It is about reaching the conversations patients are already having with each other, and making sure what gets said in those conversations is accurate, specific, and useful.
When the practical conditions of a patient's life line up with their willingness, patients give a lot: their time, their bodies, sometimes years, for research that may not benefit them directly. What they share with each other can help close the gap between wanting to participate and being able to.
Smart Patients hosts communities across more than 100 conditions. Our members participate in clinical trials, track research, and share what they know with each other and with the researchers and educators who make progress possible. If you are considering a clinical trial, or want to connect with others who have been through the process, the conversation is already happening.